Inflammatory Markers Associated with Coronary Heart Disease in Persons with HIV Infection.
Inflammatory Markers Associated with Coronary Heart Disease in Persons with HIV Infection.
复制标题
DOI：
10.1007/s11908-010-0153-9
复制
发表时间：
2011-02-01
影响因子：
3.1
通讯作者：
Fichtenbaum, Carl J
中科院分区：
文献类型：
--
作者：
Fichtenbaum, Carl J
冠心病(CHD)是一种需要几十年才能发展起来的炎症过程。在HIV血清阴性的人中，高敏C反应蛋白是CHD风险的生物标志。艾滋病毒感染导致慢性炎症，尽管抗逆转录病毒治疗充分抑制了艾滋病毒复制，导致艾滋病毒血清阴性者中与冠心病风险相关的几个生物标志物升高。事实上，SMART研究表明，中断抗逆转录病毒治疗与更高的死亡率和冠心病事件有关，这些事件被认为与炎症介质，如白细胞介素6和D-二聚体有关。特定的抗逆转录病毒药物(如阿巴卡韦)与冠心病患者心肌梗死的发生率和炎症标志物如白细胞介素6和D-二聚体的升高有关。本文综述了在HIV感染和抗逆转录病毒治疗的使用中，与CHD的发展相关的炎症生物标志物的研究现状。
Coronary heart disease (CHD) is an inflammatory process that takes decades to develop. In HIV-seronegative persons, high-sensitivity C-reactive protein is a biologic marker of CHD risk. HIV infection induces chronic inflammation, despite adequate suppression of HIV replication with antiretroviral therapy, resulting in elevations of several biologic markers associated with CHD risk in HIV-seronegative persons. Indeed, the SMART study demonstrated that interruption in antiretroviral therapy is associated with higher mortality and CHD events postulated to be related to inflammatory mediators such as interleukin-6 and D-dimer. Specific antiretroviral agents (eg, abacavir) have been associated with higher rates of myocardial infarctions and elevations in markers of inflammation such as interleukin-6 and D-dimer in persons with CHD events. This article reviews the current understanding of biomarkers of inflammation associated with the development of CHD in the setting of HIV infection and the use of antiretroviral therapy.